In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

der Heijden MS, van; JR, Brody; DA, Dezentje; E, Gallmeier; SC, Cunningham; MJ, Swartz; AM, DeMarzo; GJ, Offerhaus; WH, Isacoff; RH, Hruban; SE, Kern

doi:10.1158/1078-0432.ccr-05-1048

Public

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

Shared by NobleBlocks on Oct 1, 2005 • 12:00 AM UTC

Authors:

van der Heijden MS

Brody JR

Dezentje DA

Abstract

Purpose BRCA2, FANCC, and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to interstrand cross-linkers in vivo and a more optimal treatment of pancreatic cancer patients based on the genetic profile of the tumor.Experimental de...

Discussions